RJ CAR-T 002

RJ CAR-T 002 is a Chimeric Antigen Receptor (CAR) T-cell therapy, a type of immunotherapy that involves genetically engineering a patient's own T cells to express a synthetic receptor (CAR) on their surface. These CARs are designed to recognize and bind to specific antigens present on cancer cells, independent of the major histocompatibility complex (MHC). Upon binding, the CAR-T cells become activated, proliferate, and exert potent cytotoxic effects against the tumor cells through the release of cytokines (e.g., IL-2, IFN-γ, TNF-α) and cytolytic effector molecules like perforin and granzyme. This leads to the destruction of cancer cells and can induce long-term remission. CAR-T cell therapies are often referred to as "living drugs" due to their ability to multiply and persist in the body, continuously targeting cancer cells. While the specific target for RJ CAR-T 002 is not explicitly stated in public records, CAR-T therapies for B-cell non-Hodgkin lymphoma (B-NHL) commonly target the CD19 antigen.

Other names

CAR-T-Ruijin Hospital-B-cell non-Hodgkin lymphomaRJ CAR-T